Toll Free: 1-888-928-9744

Behcet Disease - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Behcet Disease - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Behcet Disease - Pipeline Review, H2 2016, provides an overview of the Behcet Disease (Immunology) pipeline landscape.

Behcet disease (BEH-chets), sometimes called Behcet syndrome, Morbus Behcet, or Silk Road disease, is a rare immune-mediated systemic vasculitis. The more common symptoms include sores in the mouth and on the genitals (sex organs). More serious symptoms can include inflammation (swelling, heat, redness, and pain) in the eyes and other parts of the body. The goal of treatment is to reduce pain and prevent serious problems. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Behcet Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Behcet Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Behcet Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 3, 2, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Behcet Disease.

Behcet Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Behcet Disease (Immunology).
- The pipeline guide reviews pipeline therapeutics for Behcet Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Behcet Disease (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Behcet Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Behcet Disease (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Behcet Disease (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Behcet Disease (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Behcet Disease Overview 7 Therapeutics Development 8 Pipeline Products for Behcet Disease - Overview 8 Pipeline Products for Behcet Disease - Comparative Analysis 9 Behcet Disease - Therapeutics under Development by Companies 10 Behcet Disease - Therapeutics under Investigation by Universities/Institutes 11 Behcet Disease - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Behcet Disease - Products under Development by Companies 16 Behcet Disease - Products under Investigation by Universities/Institutes 17 Behcet Disease - Companies Involved in Therapeutics Development 18 AbbVie Inc 18 Celgene Corp 19 Cell Medica Ltd 20 Coherus BioSciences Inc 21 Genor BioPharma Co Ltd 22 Iltoo Pharma 23 Mycenax Biotech Inc 24 Novartis AG 25 Panacea Biotec Ltd 26 R Pharm 27 Behcet Disease - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 adalimumab - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 adalimumab biosimilar - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 adalimumab biosimilar - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 adalimumab biosimilar - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 adalimumab biosimilar - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 aldesleukin - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 apremilast - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 canakinumab - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 DLX-105 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 infliximab biosimilar - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 pentoxifylline - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 RPH-104 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Behcet Disease - Dormant Projects 72 Behcet Disease - Discontinued Products 73 Behcet Disease - Product Development Milestones 74 Featured News & Press Releases 74 Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 74 Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet 75 Apr 15, 2015: Phase II Data for Apremilast in Behcet's Disease Published in The New England Journal of Medicine 75 Apr 14, 2015: Delenex Announces New Clinical Data 77 Jun 14, 2013: Celgene Presents Results From Phase II Trial Of Oral Apremilast In Patients With Behcet's Disease At EULAR 77 May 24, 2013: AbbVie And Eisai Receive Indication Approval For Treatment Of Intestinal Behcet Disease For Humira Pre-filled Syringe In Japan 78 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 79 Disclaimer 80
List of Tables
Number of Products under Development for Behcet Disease, H2 2016 8 Number of Products under Development for Behcet Disease - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Comparative Analysis by Unknown Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Behcet Disease - Pipeline by AbbVie Inc, H2 2016 18 Behcet Disease - Pipeline by Celgene Corp, H2 2016 19 Behcet Disease - Pipeline by Cell Medica Ltd, H2 2016 20 Behcet Disease - Pipeline by Coherus BioSciences Inc, H2 2016 21 Behcet Disease - Pipeline by Genor BioPharma Co Ltd, H2 2016 22 Behcet Disease - Pipeline by Iltoo Pharma, H2 2016 23 Behcet Disease - Pipeline by Mycenax Biotech Inc, H2 2016 24 Behcet Disease - Pipeline by Novartis AG, H2 2016 25 Behcet Disease - Pipeline by Panacea Biotec Ltd, H2 2016 26 Behcet Disease - Pipeline by R Pharm, H2 2016 27 Assessment by Monotherapy Products, H2 2016 28 Number of Products by Stage and Target, H2 2016 30 Number of Products by Stage and Mechanism of Action, H2 2016 32 Number of Products by Stage and Route of Administration, H2 2016 34 Number of Products by Stage and Molecule Type, H2 2016 36 Behcet Disease - Dormant Projects, H2 2016 72 Behcet Disease - Discontinued Products, H2 2016 73



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify